Molecular perspectives for the treatment of hepatocellular carcinoma

Area of Science:

• Genomics
• Hepatocellular Carcinoma Research
• Cancer Signaling Pathways

Background:

• Hepatocellular carcinoma (HCC) is a complex malignancy with significant genomic dysregulation.
• Understanding the genetic landscape of HCC is crucial for developing effective therapies.

Purpose of the Study:

• To elucidate the major genomic alterations in hepatocellular carcinoma.
• To correlate genetic drivers with tumor and patient phenotypes.
• To identify potential biomarkers for treatment response and new therapeutic targets.

Main Methods:

• Somatic mutation analysis of coding sequences in HCC tumors.
• Identification of frequently mutated genes and affected signaling pathways.
• Genotype/phenotype classification and correlation with transcriptomic profiling.

Main Results:

• A median of 40-60 somatic mutations per tumor, with 2-6 mutations in key liver carcinogenesis genes.
• Identified alterations in critical pathways: telomere maintenance, cell cycle, Wnt/beta-catenin, epigenetic modifiers, oxidative stress, AKT/mTOR, and Ras/Raf MAP kinase.
• Established a genotype/phenotype classification correlated with transcriptomic data.

Conclusions:

• Genomic profiling provides insights into HCC heterogeneity.
• This classification aids in predicting patient response to current systemic treatments (e.g., tyrosine kinase inhibitors, checkpoint inhibitors).
• Identified genetic drivers offer avenues for novel therapeutic strategies in future clinical trials.